When EGFR is bound to a ligand, it can activate downstream pathways such as PI3K/Akt, mTOR, or Ras/Raf/MAPK, and stimulate GBM progression, angiogenesis, and invasion. This evidence concerns the gene MTOR and glioblastoma.